Stop the Clot ™ www.stoptheclot.org David Henry and Tom Hogan Cardiovascular and Renal Drugs Advisory Committee U.S. Food and Drug Administration Adelphi,

Slides:

Advertisements

Similar presentations

10/20/ The Pharmaceutical Industry and Their Influence on Pain Management in the ED J. David Haddox, DDS, MD VP, Risk Management & Health Policy.

Advertisements

Medication Management

The Thrombosis Committee: an Instrument for Governance & Change

National Blood Clot Alliance National Survey About Blood Clots and Stroke Risk Among Atrial Fibrillation Patients Awareness, Information, Prevention, Adherence.

LHD Logo Venous Thromboembolism Reducing the Risk DATE.

Newer Anticoagulants Drug Class Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services October 16, 2013.

Spotlight Case New Oral Anticoagulants. This presentation is based on the December 2013 AHRQ WebM&M Spotlight Case –See the full article at

The views and statements expressed here are provided for informational purposes and do not necessarily reflect those of Medivo, the Alliance for Continuing.

Dr. ABDULLAH ABDU ALMIKHLAFY Assistant professor & Head of community medicine department Presented By University of Science & Technology Sana’a – Yemen.

Post oral surgery bleeding for adult patients receiving antithrombotic therapy.

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

Drug Utilization Review (DUR)

Clinical Trials Medical Interventions

The New Oral Anticoagulants: Handle with Care Philip C. Comp, M.D., Ph.D. October 18, 2013.

CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.

CONTRAST AGENTS AND RADIOPHARMACEUTICALS IN CHILDREN WITH CARDIAC DISEASE: SHOULD THEIR USE BE STUDIED? John C. Ring, MD, FAAP, FACC Associate Professor.

The EINSTEIN PE Study 'Xarelto' for the Acute and Continued Treatment of Symptomatic Pulmonary Embolism.

The EINSTEIN DVT Study 'Xarelto' for the Acute and Continued Treatment of Symptomatic Deep Vein Thrombosis.

Cardiovascular Complications After Joint Replacement Surgery: A Crossroad in Anticoagulation Vincent D. Pellegrini Jr, MD Professor and Chair Department.

1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.

Managing Warfarin Drug Interactions: The Bayview Experience DAWN Users Group, November 2002 Charles H. Twilley, MBA, PharmD Johns Hopkins Bayview Medical.

The EINSTEIN EXT Study 'Xarelto' for the Long-Term Prevention of Recurrent Venous Thromboembolism.

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Mark Bleackley MEDG 505 March.

Managing Hepatitis C: An Unprecedented Correctional Healthcare Challenge ASCA/CCHA meeting Phoenix, AZ RADM Newton E. Kendig Assistant Director/Medical.

Study Guide Guide for Patients Undergoing Anticoagulant Therapy.

Antiplatelet or Anticoagulant: Do They Have the same Efficacy? University of Central Florida Deborah Andrews RN, BSN.

Social Pharmacy Lecture no. 8 Rational prescribing guidelines.

Topic 10 Patient safety and invasive procedures. Learning objective The objective of this topic is to understand the main causes of adverse events in.

National Blood Clot Alliance National Survey About Deep Vein Thrombosis and Pulmonary Embolism Awareness, Information, Prevention, Adherence Key Survey.

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College.

Preventing Surgical Complications Prevent Harm from High Alert Medication- Anticoagulants in Primary Care Insert Date here Presenter:

National Blood Clot Alliance National Survey About Deep Vein Thrombosis and Pulmonary Embolism Awareness, Information, Prevention, Adherence Key Survey.

CHEE DRUG PRODUCT DEVELOPMENT u Drug ä agent intended for use in the diagnosis, mitigation, treatment, cure, or prevention of disease in man or animals.

The Role of Thromboprophylaxis in Elective Spinal Surgery The Role of Thromboprophylaxis in Elective Spinal Surgery VA Elwell, N Koo Ng, D Horner & D Peterson.

Rivaroxaban for Prevention of Venous Thromboembolism After Total Knee Arthroplasty: Impact on Healthcare Costs Based on the RECORD3 Study Kwong L, Lees.

Legal & Ethical Issues. Objectives At the completion of this session the participant will be able to: ◦ Describe the ethical principles associated with.

Food and Drug Administration

NORTH AMERICAN HEALTHCARE COMMITTEES. POLICY Facility shall have at least the following committees: Resident Care Infection Control Pharmaceutical Quality.

ALI R. RAHIMI, BOBBY WRIGHTS, MD, HOSSEIN AKHONDI, MD & CHRISTIAN M. RICHARD, MSC Clinical Correlation Between Effective Anticoagulants & Risk of Stroke:

Orlistat 60 mg Joint Meeting Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committees January 23, 2006 Andrea Leonard-Segal, M.D.

Anticoagulants Reducing the risk Amanda Powell & Sue Wooller May 2014.

Topic 10 Patient safety and invasive procedures. LEARNING OBJECTIVE The objective of this topic is to understand the main causes of adverse events in.

7asdf Omapatrilat in the Treatment of Hypertension NDA FDA Cardiovascular and Renal Drugs Advisory Committee Meeting July 19, 2002 Anthony Waclawski,

Praxbind® - Idarucizumab

Confidential: Quality Improvement Material Reducing Clotting Events for Post-Surgical Orthopedic Patients Loyola Anticoagulation Clinic Spring 2009.

Agents Affecting Blood Clotting

Challenges to drug design Did you know? Over 2 million people are hospitalized each year for adverse reactions to prescription drugs. Over 2 million.

Chapter 19 Agents affecting Blood Clotting. Blood Clotting p461 Clotting is necessary to prevent fatal loss of blood from a minor injury Thromboemboli.

Purpose of Clinical Trials Assess safety and efficacy of Experimental treatments New combinations of drugs New approaches to surgery or radiation therapies.

Together we can do so much February 5th , 2016:

Long-term Efficacy for Psychiatric Drugs Frederick K. Goodwin, MD George Washington University Medical Center Frederick K. Goodwin, MD George Washington.

 Pharmaceutical Care is a patient-centered, outcomes oriented pharmacy practice that requires the pharmacist to work in concert with the patient and.

Treatment and Prevention of Heparin- Induced Thrombocytopenia Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.

27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.

Clinical Research Contribution towards improving Clinical Care

Rapid Reversal of Warfarin Therapy in Patients with Intracranial / Intraspinal Bleeding Mount Auburn Hospital Blood Bank, Emergency Department, Critical.

Treatment and Prevention of Heparin-Induced Thrombocytopenia

Clinical Trials — A Closer Look

Clinical Trials Medical Interventions

Bozeman Health Clinical Research

Opioid Prescribing & Monitoring

Clinical Trials.

Reversal of Direct Oral Anticoagulants (DOAC)

Extraordinary Cases of VTE Prevention in Patients With Cancer

Pharmacogenomics Genes and Drugs.

Management of Systematic Lupus Erythematosus

What is Patient Blood Management?

Clinical Practice Guidelines: What, Why, Who?

ADAS Anticoagulant Dosing and Advisory Service

Presentation transcript:

Stop the Clot ™ David Henry and Tom Hogan Cardiovascular and Renal Drugs Advisory Committee U.S. Food and Drug Administration Adelphi, MD March19, 2009

Stop the Clot ™ NATT Community-based, patient led, science driven volunteer organization Committed to prevention and quality treatment of blood clots and clotting disorders

Stop the Clot ™ NATT’s Mission... To prevent, diagnose and treat thrombosis and thrombophilia through research, education, support and advocacy

Stop the Clot ™ NATT-CDC COOPERATIVE AGREEMENT Patient Education and Support Health Professional Education Website Development Development of Nationwide Chapter Network

Stop the Clot ™ SURGEON GENERAL’S CALL TO ACTION TO PREVENT DVT/PE Issued September 2008 Spotlights public health urgency posed by DVT/PE

Stop the Clot ™ CALL TO ACTION PUBLIC HEALTH THREAT Surgeon General’s Report 350, ,000 Americans have blood clots every year 100,000 deaths Blood clots are a leading cause of death!

Stop the Clot ™ MAYO CLINIC DATA (Heit et al) 900,000 Americans have blood clots every year 300,000 deaths Blood clots are a leading cause of death!

Stop the Clot ™ PRIORITY - REINFORCE EVIDENCE-BASED PREVENTION Majority of at-risk patients with confirmed DVT were not prophylaxed, despite risk, and availability of evidence-based guidelines

Stop the Clot ™ SURGEON GENERAL RECOMMENDATIONS Encourage development of new pharmaceutical agents with fewer adverse effects of existing agents: Faster onset Wider therapeutic range Fewer food or drug interactions

Stop the Clot ™ SURGEON GENERAL RECOMMENDATIONS Conduct further research on anticoagulants: Best or optimal choice for designated populations Safest dosing

HIP/KNEE REPLACEMENT TRENDS 2005< 1 Million 2009Nearly 1.2 Million Future Aging Baby Boomers Stop the Clot ™

Stop the Clot ™ NEED TO REINFORCE ESTABLISHED GUIDELINES Reluctance of orthopedists to implement prophylaxis on patients with knee and hip replacement Major Concern: BLEEDING A clot is an act of God, whereas bleeding is surgical error

Tom Hogan Stop the Clot ™

Stop the Clot ™ POTENTIAL BENEFITS OF NEW ORAL MEDICATION No INR monitoring Pill instead of injection Minimal diet concerns (e.g. vitamin K) Minimal worry about interaction with other medication Quick action and rapid elimination (onset-offset)

Stop the Clot ™ If potential benefits are realized… Close to optimal care + Reduced risks for complications = Increased acceptance/use for TKR/THR + Reduced morbidity and mortality

Stop the Clot ™ NATT SUMMARY Supports Surgeon General Call to Action Appreciates the safety and efficacy review that will be done by committee If approval is recommended, urges expeditious consideration by FDA